Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy
Molecules · 27.03.2026 · 31 (7) · 1103
DOI: 10.3390/molecules31071103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 27.03.2026. Verfasst von Goreti Ribeiro Morais und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK. Hauptthemen laut MEDLINE: Triazenes, Temozolomide, Prodrugs, Dacarbazine. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Masonic Charitable Foundation.
Abstract (Originalsprache)
Temozolomide and dacarbazine are untargeted anticancer prodrugs that have been widely employed in the treatment of melanoma and glioblastoma. These agents decompose into a short-lived monomethyl triazene intermediate, culminating in the release of a methyl diazonium cation that serves as the DNA-alkylating species responsible for tumour destruction. However, due to their high chemical lability, these agents have been associated with chemotherapy resistance, mutagenicity, tumour relapse, and significant off-target toxicity. One promising strategy towards the resolution of these limitations involves the design of arylmethyl triazene prodrugs, which enable targeted tumour-specific drug delivery. This review explores the various approaches used to selectively deliver alkyl aryl triazenes as alternatives to current therapies. It highlights early chemical strategies such as N-acylation and etherification of monomethyl triazenes, along with associated kinetic studies. The selective activation of novel triazenes in murine and human melanoma cells through a tyrosinase-responsive promoiety is discussed. Recent progress in nitroaromatic-based prodrugs designed to exploit the hypoxic microenvironment of glioblastoma is also examined. Additionally, we summarise the development of combi-triazenes and their underlying chemistries, which enable the simultaneous release of two active therapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK.
ORCID-Profile: Goreti Ribeiro Morais, Gabriel C Nwokolo, Harriet N L Lamptey Mills, Richard T Wheelhouse, Robert A Falconer
Förderung
- Masonic Charitable Foundation
Zitieren
APA
Ribeiro Morais, G., Nwokolo, G. C., Lamptey Mills, H. N. L., Wheelhouse, R. T., & Falconer, R. A. (2026). Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy. Molecules, 31(7), 1103. https://doi.org/10.3390/molecules31071103
Vancouver
Ribeiro Morais G, Nwokolo GC, Lamptey Mills HNL, Wheelhouse RT, Falconer RA. Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy. Molecules. 2026;31(7):1103. doi:10.3390/molecules31071103
BibTeX
@article{RibeiroMorais2026,
author = {Ribeiro Morais, Goreti and Nwokolo, Gabriel C and Lamptey Mills, Harriet N L and Wheelhouse, Richard T and Falconer, Robert A},
title = {Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy},
journal = {Molecules},
year = {2026},
volume = {31},
number = {7},
pages = {1103},
doi = {10.3390/molecules31071103}
}
EUVIMED